Moscow, 23 January, 2008 – OJSC Pharmstandard (LSE: PHST LI, RTS: PHST RU) announces an acquisition of 19,88% shares of «DIPAKA TRAIDING LIMITED», Cyprus, for US$10 million. Pharmstandard financed the transaction through the operational cash-on-hand.

«DIPAKA TRAIDING LIMITED» owns 100% shares of Russian pharmaceutical company Mirpharm and several patents and trademarks, including Mexiprim®. Mirpharm is Russian highly technological API producer and holds research base for drugs and APIs development.

According to contract with Mirpharm Pharmstandard accomplishes exclusive distribution and promotion of Mexiprim®. In future Pharmstandard plans to use Mirpharm R&D resources for development and production of drugs and APIs.